HOME > News > Chiesi Farmaceutici...

We wish to inform you that law no. 196/03 protects people
and other subjects as concerns the use of personal details.
Edit email address
Invialid email
Email Sent
Accept privacy law

Chiesi Farmaceutici completes the acquisition of European Marketing Rights to PROCYSBI® (cysteamine bitartrate) delayed-release capsules and QUINSAIR™ (levofloxacin inhalation solution) in Europe, Middle East and Africa (EMEA) Regions from Horizon Phar

Date: 23/06/2017

Parma (Italy) – June 23, 2017 – Chiesi Farmaceutici S.p.A. (Chiesi Group), an international research-focused Healthcare Group, announces today that it has completed the acquisition of a European subsidiary of Horizon Pharma that owns the marketing rights to PROCYSBI® (cysteamine bitartrate) delayed-release capsules and QUINSAIR (levofloxacin inhalation solution) in Europe, the Middle East and Africa (EMEA).

Horizon will maintain control of manufacturing supply in the EMEA regions through its third party supplier.  In addition, Horizon will maintain marketing rights for PROCYSBI and QUINSAIR in the United States, Canada and Latin America. 

“Procysbi is indicated for nephropathic cystinosis, a very rare genetic condition that affects approximately 2000 people in the world,” says Ugo Di Francesco, Chiesi Group CEO “while Quinsair) is an antibiotic used for long-term lung infection in adults with cystic fibrosis (CF). Chiesi has a strong commitment to the rare disease area and these products are an important opportunity to enhance our portfolio and contribute to improve the quality of life of nephropathic cystinosis and cystic fibrosis patients.”